UNSPSC 51434905: Alskiren/amlodipine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434905 Aliskiren/amlodipine is a Commodity code covering combination antihypertensive pharmaceuticals. State and local governments procure under this code primarily through emergency medical services and public health agencies seeking Advanced Life Support medications and broader generic pharmaceutical supply agreements. The City of Tampa's Fire Rescue procurement illustrates the operational scope — sealed bids for specific medication units (Labetalol, Epinephrine, Adenosine, Diltiazem) with firm pricing including freight and overnight expiration-date warranties. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products, which covers this code and related therapeutics, shows state and local procurement also extends to cooperative contracting with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) serving multiple state and local facilities across participating jurisdictions. Issuing bodies include city purchasing departments (Tampa), state health agencies (Texas HHS Commission), and cooperative purchasing alliances administering contracts for state and local government users. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and comprehensive insurance coverage (general liability up to $5 million, network security and privacy liability $2 million).

The code shows recent activity across Florida, Texas, and Minnesota–Oregon through the MMCAP cooperative. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications with a response due April 8, 2026, and estimated contract value of $40,000, featuring a 5 percent SLBE bid discount (not to exceed $10,000) and one-year initial term with two optional one-year renewals plus unilateral 30-day extensions. The Minnesota Department of Administration issued an RFP through MMCAP (S1070000015802) due March 26, 2026, establishing multi-award contracts for generic pharmaceuticals effective July 1, 2026, with two-year terms, evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription fulfillment models, signaling potential future formal procurement but without committed budget or award values.